<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925804</url>
  </required_header>
  <id_info>
    <org_study_id>HPP genetics-2020</org_study_id>
    <nct_id>NCT04925804</nct_id>
  </id_info>
  <brief_title>Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)</brief_title>
  <official_title>Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study to perform Whole Genome Sequencing in participants clinically suspected&#xD;
      for HPP and negative for known pathogenic ALPL variants&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypophosphatasia (HPP) is a rare Inborn Error of Metabolism (IEM), characterized by low&#xD;
      tissue-nonspecific isoenzyme of alkaline phosphatase (ALP) activity. Alkaline phosphatase&#xD;
      (ALP) is crucial for osteoid mineralization. Its main substrate in bone is pyrophosphate&#xD;
      (PPi), a natural inhibitor of mineralization. ALP cleaves pyrophosphate into its two&#xD;
      phosphate moieties, which then become available to the mineralization process. This ALP&#xD;
      deficiency results in accumulation of its substrates, mainly inorganic pyrophosphate (PPi),&#xD;
      pyridoxal-5-phosphate (PLP), and phosphoethanolamine (PEA).&#xD;
&#xD;
      Beyond the bone and the Central Nervous System (CNS), ALP deficiency has an impact on a&#xD;
      number of other organs and systems, resulting in a broad range of manifestations, including&#xD;
      dental (premature tooth loss), muscular (muscle weakness, delayed walking, abnormal gait),&#xD;
      rheumatic (calcium pyrophosphate deposition disease, fibromyalgia, fatigue, joint laxity),&#xD;
      eye (calcifications), renal (nephrocalcinosis, kidney stones, renal failure), and&#xD;
      gastrointestinal tract disturbance (gastroesophageal reflux).&#xD;
&#xD;
      The specific symptoms can vary greatly from one person to another, sometimes even among&#xD;
      members of the same family. There are five major clinical forms of HPP (perinatal, infantile,&#xD;
      childhood, adult, and odontohypophosphatasia), ranging from an extremely severe form that can&#xD;
      cause stillbirth to a form associated with only premature loss of baby (deciduous) teeth, but&#xD;
      no bone abnormalities.&#xD;
&#xD;
      The genetic reason of Hypophosphatasia is mainly caused by mutations in the ALPL gene, coding&#xD;
      for the tissue nonspecific alkaline phosphatase isoenzyme. At least 397 distinct pathogenic&#xD;
      variants (predominantly missense variants) were described to lead to low levels of the ALP&#xD;
      enzyme. HPP can be inherited in an autosomal recessive (most perinatal and infantile forms)&#xD;
      or autosomal dominant manner (typically the adult form and odontohypophosphatasia).&#xD;
&#xD;
      Since ALPL dependent prevalence is very low, while symptoms overlapping HPP are much more&#xD;
      common, other primary - genetic - forms of HPP-like symptoms are to be sought and&#xD;
      characterized.&#xD;
&#xD;
      The HPP genetics study aims to characterize the genetic background of HPP participants, who&#xD;
      do not have pathogenic variant/s in the ALPL gene.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic analysis (WGS) of participants clinically suspected for HPP</measure>
    <time_frame>6 months</time_frame>
    <description>Analyis of Whole Genome Sequencing data in participants clinically suspected for HPP disease to characterize the genetic background of these 16 HPP subjects, who do not have pathogenic variant/s in the ALPL gene.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis and identification of genetic variants</measure>
    <time_frame>6 months</time_frame>
    <description>Identification and validation of genetic variants in the selected cohort (16 WGS subjects; see Outcome 1) since ALPL dependent prevalence is very low, while symptoms overlapping HPP are much more common, other primary - genetic - forms of HPP-like symptoms are to be sought and characterized.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Hypophosphatasia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on Dry Blood Spot (DBS) Filtercard (CentoCard®)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The participant is clinically suspected for HPP with no pathogenic variant/s in the ALPL&#xD;
        gene&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Informed consent is obtained from the participant or from the parent / legal guardian&#xD;
&#xD;
          -  The participant is clinically suspected for HPP&#xD;
&#xD;
          -  The participant does not have pathogenic variant/s in the ALPL gene&#xD;
&#xD;
          -  The participant showed low alkaline phosphatase levels (age- and sex-adjusted) on at&#xD;
             least two occasions at least a month apart based on the local laboratory reference&#xD;
             range&#xD;
&#xD;
          -  None of these conditions are present:&#xD;
&#xD;
               -  Celiac disease and&#xD;
&#xD;
               -  Clofibrate therapy and&#xD;
&#xD;
               -  Cleidocranial dysplasia and&#xD;
&#xD;
               -  Cushing's syndrome and&#xD;
&#xD;
               -  Hypothyroidism and&#xD;
&#xD;
               -  Massive Blood transfusion and&#xD;
&#xD;
               -  Milk-alkali syndrome and&#xD;
&#xD;
               -  Multiple myeloma and&#xD;
&#xD;
               -  Osteogenesis imperfecta, type II and&#xD;
&#xD;
               -  Pernicious or profound anemia and&#xD;
&#xD;
               -  Starvation and&#xD;
&#xD;
               -  Vitamin C deficiency and&#xD;
&#xD;
               -  Vitamin D intoxication and&#xD;
&#xD;
               -  Zinc deficiency and&#xD;
&#xD;
               -  Magnesium deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>CENTOGENE GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anika Knaust, PhD</last_name>
    <phone>+49 38180113633</phone>
    <email>anika.knaust@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Reder, M.Sc.</last_name>
    <phone>+49 38180113739</phone>
    <email>felix.reder@centogene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universität Würzburg - Klinische Studieneinheit, Orthopädische Klinik</name>
      <address>
        <city>Würzburg</city>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lothar Seefried, MD</last_name>
      <phone>+49 931 803 3590</phone>
      <email>l-seefried.klh@uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Lothar Seefried, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypophosphatasia</keyword>
  <keyword>HPP</keyword>
  <keyword>non-ALPL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is possible, but not determined, yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

